- Home
- TCRX vs SRTS Comparison
TCRX vs SRTS Comparison
Compare TCRX & SRTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TCRX
- SRTS
- Stock Information
- Founded
- TCRX 2018
- SRTS 2010
- Country
- TCRX United States
- SRTS United States
- Employees
- TCRX N/A
- SRTS N/A
- Industry
- TCRX Biotechnology: Pharmaceutical Preparations
- SRTS Medical/Dental Instruments
- Sector
- TCRX Health Care
- SRTS Health Care
- Exchange
- TCRX Nasdaq
- SRTS Nasdaq
- Market Cap
- TCRX 100.7M
- SRTS 83.9M
- IPO Year
- TCRX 2021
- SRTS 2016
- Fundamental
- Price
- TCRX $1.44
- SRTS $4.71
- Analyst Decision
- TCRX Strong Buy
- SRTS Strong Buy
- Analyst Count
- TCRX 6
- SRTS 3
- Target Price
- TCRX $9.50
- SRTS $11.67
- AVG Volume (30 Days)
- TCRX 470.2K
- SRTS 56.8K
- Earning Date
- TCRX 08-11-2025
- SRTS 08-07-2025
- Dividend Yield
- TCRX N/A
- SRTS N/A
- EPS Growth
- TCRX N/A
- SRTS N/A
- EPS
- TCRX N/A
- SRTS 0.11
- Revenue
- TCRX $4,421,000.00
- SRTS $39,488,000.00
- Revenue This Year
- TCRX $159.20
- SRTS $4.33
- Revenue Next Year
- TCRX N/A
- SRTS $31.55
- P/E Ratio
- TCRX N/A
- SRTS $42.74
- Revenue Growth
- TCRX N/A
- SRTS 24.75
- 52 Week Low
- TCRX $1.02
- SRTS $4.01
- 52 Week High
- TCRX $7.89
- SRTS $9.33
- Technical
- Relative Strength Index (RSI)
- TCRX 44.26
- SRTS 50.14
- Support Level
- TCRX $1.44
- SRTS $4.72
- Resistance Level
- TCRX $1.61
- SRTS $5.02
- Average True Range (ATR)
- TCRX 0.16
- SRTS 0.21
- MACD
- TCRX -0.02
- SRTS -0.03
- Stochastic Oscillator
- TCRX 10.44
- SRTS 27.12
About TCRX TScan Therapeutics Inc.
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.
About SRTS Sensus Healthcare Inc.
Sensus Healthcare Inc is engaged in manufacturing a superficial radiotherapy system. These devices are used for treating both oncological and non-oncological skin conditions including basal cell and squamous cell skin cancers and other skin conditions such as keloids. Its product includes SRT-100, SRT-100 vision, and a sentinel service program. The company's revenue is generated majorly from customers in the United States.